Donaldson Co Inc
Donaldson Co Inc operates as a global filtration and fluid management solutions provider, generating revenue through its Mobile Solutions, Industrial Solutions, and Life Sciences segments.
Business. DONALDSON Co Inc (NYSE: DCI) is a company operating within the Oil & Gas Exploration & Production industry, primarily engaged in exploration and production activities. The firm generates revenue through a product-sale model and is headquartered in the United States. As segment and geographic breakdowns are not specified, the company is described at the industry level. It is primarily listed on the New York Stock Exchange under the ticker symbol DCI.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-09-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressKim Dr Schrier — Donaldson Company, Inc.2021-10-28 · Democrat · WA · Sale · $1,001 - $15,000
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
DONALDSON Co Inc (NYSE: DCI) is a company operating within the Oil & Gas Exploration & Production industry, primarily engaged in exploration and production activities. The firm generates revenue through a product-sale model and is headquartered in the United States. As segment and geographic breakdowns are not specified, the company is described at the industry level. It is primarily listed on the New York Stock Exchange under the ticker symbol DCI.
Donaldson maintains a conservative capital structure with a debt-to-equity ratio of 0.36 and a current ratio of 2.35, indicating strong short-term liquidity coverage. Total equity stands at $1.70 billion against total liabilities of $1.39 billion, while long-term debt is limited to $591.6 million. The company holds $204.1 million in cash and equivalents, resulting in a net cash position that is technically negative when total debt is subtracted, though the low leverage profile mitigates immediate solvency concerns. Operating cash flow of $293.8 million comfortably covers capital expenditures of $52.5 million, yielding free cash flow of $241.3 million.
Profitability metrics reflect strong operational efficiency, with a return on equity of 19.14% and return on assets of 10.51%. The company reports a gross profit of $962.0 million and operating income of $423.3 million for the nine months ended April 30, 2026, demonstrating robust margin expansion compared to the prior year’s operating income of $343.7 million. Net income reached $324.5 million, up from $252.7 million in the same period last year, driven by higher net sales of $2.83 billion versus $2.71 billion. The valuation multiples are elevated, with a P/E of 32.03 and EV/EBITDA of 21.75, suggesting the market prices in significant future growth or stability.
Revenue is diversified across three reportable segments: Mobile Solutions, Industrial Solutions, and Life Sciences. The company’s strategy focuses on extending market access in bioprocessing and alternative power solutions, while expanding industrial connected service offerings. This segment structure allows Donaldson to balance cyclical exposure in mobile and industrial markets with higher-margin growth opportunities in life sciences.
Growth trajectory shows consistent top-line and bottom-line expansion, with net sales increasing 4.3% year-over-year to $2.83 billion for the nine-month period. Net earnings per share (diluted) rose to $2.75 from $2.09, reflecting both revenue growth and share count reduction through buybacks. The company reduced diluted shares outstanding from 121.2 million to 117.9 million, enhancing per-share metrics.
Risk assessment indicates medium liquidity and dilution risks, with key flags noting negative net cash after total debt subtraction and source documents mentioning dilution or offering risk. The company’s reliance on strategic acquisitions for growth introduces integration and valuation risks, while the medium dilution risk suggests potential future equity issuance or option exercises.
Recent events include an 8-K filing with Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), indicating significant corporate governance changes. Analyst sentiment is mixed, with a mean recommendation of 2.50 (Hold) and a mean price target of $95.93, implying modest upside from the current price of $88.17.
- Strong profitability with 19.14% ROE and 10.51% ROA, supported by expanding operating margins.
- Conservative balance sheet with 0.36 debt-to-equity and 2.35 current ratio, though net cash is negative.
- Consistent revenue growth of 4.3% YoY and 32.4% YoY net income growth for the nine months ended April 2026.
- Elevated valuation multiples (P/E 32.03, EV/EBITDA 21.75) reflect high growth expectations.
- Medium dilution risk flagged due to potential equity offerings and option exercises.
- Recent 8-K filing indicates significant executive or director changes, requiring monitoring.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income $423.3M.
- ▍Operating income $423.3M
Operating income $268.0M.
- ▍Operating income $268.0M
Operating income $149.3M.
- ▍Operating income $149.3M
Operating income $495.4M.
- ▍Operating income $495.4M
Operating income $544.1M.
- ▍Operating income $544.1M
Operating income $544.1M.
- ▍Operating income $544.1M
Operating income $480.2M.
- ▍Operating income $480.2M
Operating income $480.2M.
- ▍Operating income $480.2M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Stock Option (right to buy) → Common StockDisposed 7 153 @ $42,26exercise · 2026-04-14
- Director · Stock Option (right to buy) → Common StockDisposed 6 600 @ $48,96exercise · 2026-04-14
- Director · Stock Option (right to buy) → Common StockDisposed 5 921 @ $42,26exercise · 2026-04-13
- Director · Stock Option (right to buy) → Common StockDisposed 126 @ $42,26exercise · 2026-04-10
- President · Employee Stock Option (right to buy) → Common StockDisposed 8 600 @ $45,43exercise · 2026-03-26
- President · Employee Stock Option (right to buy) → Common StockDisposed 12 000 @ $42,72exercise · 2026-03-26
- President · Employee Stock Option (right to buy) → Common StockAcquired 15 500 @ $95,72grant · 2026-03-02
- Director · Stock Option (right to buy) → Common StockAcquired 3 000 @ $89,93grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 3 000 @ $89,93grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 3 000 @ $89,93grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 3 000 @ $89,93grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 3 000 @ $89,93grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 3 000 @ $89,93grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 3 000 @ $89,93grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 3 000 @ $89,93grant · 2026-01-02
- Director · Stock Option (right to buy) → Common StockAcquired 3 000 @ $89,93grant · 2026-01-02
- Chief Financial Officer · Employee Stock Option (right to buy) → Common StockDisposed 1 000 @ $28,00exercise · 2025-12-09
- Director · Stock Option (right to buy) → Common StockAcquired 200 @ $91,76grant · 2025-12-08
- Director · Stock Option (right to buy) → Common StockDisposed 6 600 @ $48,96exercise · 2025-12-05
- Director · Stock Option (right to buy) → Common StockDisposed 13 200 @ $42,26exercise · 2025-12-05
- Chief Financial Officer · Employee Stock Option (right to buy) → Common StockAcquired 23 900 @ $82,08grant · 2025-10-01
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- DONALDSON Co INC company facts · 2026-07-26
- DONALDSON Co INC 10-Q 2026-06-02 · 2026-07-26
- DONALDSON Co INC 10-Q 2026-02-26 · 2026-07-26
- DONALDSON Co INC 10-Q 2025-12-04 · 2026-07-26
- DONALDSON Co INC 10-K 2025-09-26 · 2026-07-26
- 8-K (sec_8k_material) on DCI · 2026-07-26
- Donaldson Company Inc Market data — analyst estimates · 2026-07-26
- Donaldson Company Inc Market data — ESG · 2026-07-26
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,07 %$140M
- Investment Managers · as of 2026-03-310,06 %$88M
- Investment Managers · as of 2026-03-310,04 %$59M
- Investment Managers · as of 2026-03-310,04 %$169M
- Funds · as of 2026-03-310,03 %$195M
- Investment Managers · as of 2026-03-310,03 %$62M
- Institutional Investor · as of 2022-09-300,03 %$0M
- Investment Managers · as of 2026-03-310,02 %$40M
- Institutional Investor · as of 2026-03-310,02 %$104M
- Institutional Investor · as of 2026-03-310,02 %$38M
- Institutional Investor · as of 2026-03-310,02 %$56M
- Investment Managers · as of 2026-03-310,02 %$283M
- Investment Managers · as of 2024-06-300,02 %$773M
- Institutional Investor · as of 2026-03-310,02 %$325M
- Investment Managers · as of 2025-12-310,02 %$1 047M
- Investment Managers · as of 2026-03-310,01 %$405M
- Investment Managers · as of 2026-03-310,01 %$98M
- Investment Managers · as of 2026-03-310,01 %$205M
- Investment Managers · as of 2026-03-310,01 %$22M
- Investment Managers · as of 2026-03-310,01 %$69M
- Brokerage Firms · as of 2026-03-310,01 %$51M
- Investment Managers · as of 2026-03-310,01 %$52M
- Brokerage Firms · as of 2026-03-310,01 %$23M
- Investment Managers · as of 2024-12-310,01 %$18M
- Investment Managers · as of 2026-03-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$24M
- Institutional Investor · as of 2026-03-310,00 %$12M
- Institutional Investor · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Director · Common StockOther 267 @ $89,09$24K · 2026-07-03
- Director · Common StockOther 400 @ $89,09$36K · 2026-07-03
- Director · Common StockOther 267 @ $89,09$24K · 2026-07-03
- Director · Common StockOther 334 @ $89,09$30K · 2026-07-03
- Director · Common StockSold 7 153 @ $89,21$638K · 2026-04-14
- Director · Common StockOther 6 600 @ $48,96$323K · 2026-04-14
- Director · Common StockSold 6 600 @ $89,21$589K · 2026-04-14
- Director · Common StockOther 7 153 @ $42,26$302K · 2026-04-14
- Director · Common StockOther 5 921 @ $42,26$250K · 2026-04-13
- Director · Common StockSold 5 921 @ $89,02$527K · 2026-04-13
- Director · Common StockOther 126 @ $42,26$5K · 2026-04-10
- Director · Common StockSold 126 @ $88,82$11K · 2026-04-10
- Director · Common StockOther 279 @ $85,23$24K · 2026-04-03
- Director · Common StockOther 349 @ $85,23$30K · 2026-04-03
- Director · Common StockOther 279 @ $85,23$24K · 2026-04-03
- Director · Common StockOther 418 @ $85,23$36K · 2026-04-03
- President · Common StockOther 12 000 @ $42,72$513K · 2026-03-26
- President · Common StockSold 12 000 @ $84,97$1,0M · 2026-03-26
- President · Common StockOther 8 600 @ $45,43$391K · 2026-03-26
- President · Common StockSold 8 600 @ $84,97$731K · 2026-03-26
- Director · Common StockOther 900 · 2026-01-02
- Director · Common StockOther 250 @ $89,93$22K · 2026-01-02
- Director · Common StockOther 900 · 2026-01-02
- Director · Common StockOther 900 · 2026-01-02
- Director · Common StockOther 311 @ $89,93$28K · 2026-01-02
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Cash & equivalents (YoY) (2026-01-31 vs 2025-01-31): 2.8%Derived (calculated)
- Debt-to-equity (FY 2026-01-31): 0.94xDerived (calculated)
- Total liabilities (YoY) (2026-01-31 vs 2025-01-31): 4.8%Derived (calculated)
- Current ratio (FY 2026-01-31): 2.29xDerived (calculated)
- Total assets (YoY) (2026-01-31 vs 2025-01-31): 3.3%Derived (calculated)
- Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): 2.0%Derived (calculated)
- Shareholders' equity (annual): USD 1.58BSEC XBRL filing
- Total liabilities (annual): USD 1.49BSEC XBRL filing
- Current assets (annual): USD 1.53BSEC XBRL filing
- Total assets (annual): USD 3.06BSEC XBRL filing
- Cash & equivalents (annual): USD 194.4MSEC XBRL filing
- Current liabilities (annual): USD 665.9MSEC XBRL filing
- EPS (diluted) (YoY) (2025-07-31 vs 2024-07-31): -9.8%Derived (calculated)
- Capex (YoY) (2025-07-31 vs 2024-07-31): -7.8%Derived (calculated)
- Cost of revenue (YoY) (2025-07-31 vs 2024-07-31): 4.0%Derived (calculated)
- Operating income (YoY) (2025-07-31 vs 2024-07-31): -9.0%Derived (calculated)
- Gross profit (YoY) (2025-07-31 vs 2024-07-31): 0.9%Derived (calculated)
- Operating cash flow (YoY) (2025-07-31 vs 2024-07-31): -15.0%Derived (calculated)
- EPS (basic) (YoY) (2025-07-31 vs 2024-07-31): -9.9%Derived (calculated)
- R&D expense (YoY) (2025-07-31 vs 2024-07-31): -6.2%Derived (calculated)
- Net income (YoY) (2025-07-31 vs 2024-07-31): -11.4%Derived (calculated)
- Total operating expenses (annual): USD 790.8MSEC XBRL filing
- Operating income (annual): USD 495.4MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 3SEC XBRL filing